Novo Holdings, the parent company of Danish pharmaceutical giant Novo Nordisk, reported a significant decline in the value of its managed assets throughout 2025. The company's assets fell by more than one-third, primarily driven by a steep drop in Novo Nordisk's stock price over the year.
Novo Nordisk has been one of the most prominent beneficiaries of the obesity drug boom, with its Ozempic and Wegovy medications generating massive revenue growth. However, increasing competition in the GLP-1 drug market and concerns about pricing pressure have weighed on investor sentiment toward the company.